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Background: EGFR mutation detection has been widely applied in the prediction of TKIs therapy in Non-Small Cell
Lung Cancer (NSCLC). Metastatic tumors rather than primary tumors were usually assayed for those patients in
advanced stages. Although the difference of EGFR mutation status in primary and metastatic tumors has been
reported, the quantitative difference (ratio of mutated EGFR among total EGFR) in primary and metastatic tumors
as well as in different sites of primary tumors was not clear.
Methods: Genomic DNA in Formalin Fixed-Paraffin Embedded samples of primary and metastatic tumors of 50
NSCLC patients was extracted. Real-time fluorescent PCR was performed to quantify the EGFR mutation ratios.
Results: The EGFR mutation ratios detected in different sites of primary tumors were highly concordant, whereas
the EGFR mutation ratios in metastatic tumors were lower than those in primary tumors.
Conclusions: Randomly chosen sample may reliably represent the type and ratio of mutations of EGFR in primary
tumors. EGFR mutation ratios in primary tumors and metastatic tumors are different. If metastatic tumors are used
for the detection of EGFR mutation, the sensitivity of the detection assay must be considered.
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Epidermal growth factor receptor (EGFR) is a receptor
tyrosine kinase encoded by the c-erb-B1 proto-oncogene.
Multiple studies showed that the efficacy of tyrosine kin-
ase inhibitors (TKIs) in the treatment of Non-Small Cell
Lung Cancer (NSCLC) is highly correlated with EGFR
mutation status in exon 18–21 [1-4].
EGFR mutations have been detected in 30-50% of
NSCLC patients in China [5,6]. The detection methods in-
clude PCR-sequencing, Taqman real-time PCR, DHPLC,
and SARMS [6-12]. For some of the NSCLC patients, es-
pecially those with metastatic cancer, the primary tumor
specimen may not be available; therefore EGFR mutations
in metastases are often analyzed. However, the molecular
nature of the tumors may change during metastasis, and
currently it is unclear whether the mutations detected
in primary tumors correlate with those in metastases. It
has been reported that EGFR mutations detected in* Correspondence: majie@medmail.com.cn
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stated.metastases are 10-60% inconsistent with those in primary
tumors [13,14]. It is worth noting that gefitinib has been
reported to be beneficial for patients in which EGFR mu-
tations were detected in metastases but not primary tu-
mors [15]. However, since these studies used qualitative
detection of EGFR mutations, it is impossible to quantita-
tively evaluate the abundance of EGFR mutations in the
primary tumor and metastases.
Real-time fluorescent PCR detection of mutations is a
straightforward method with high sensitivity and reliabil-
ity. In this study, we used real-time PCR to quantita-
tively detect EGFR mutations in primary and metastatic
tumors. Fifty Chinese NSCLC patients that harbor EGFR
mutations in their primary tumors were identified. EGFR
mutation status and abundance were compared among
different areas of a primary tumor and its corresponding
metastatic tumor of the same individual. Our study pro-
vides new insights on clinical interpretation of EGFR
mutation status in different specimens.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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Patients and Clinical Characteristics
From the patients who visited Henan Cancer Hospital be-
tween January 2010 and December 2012, those diagnosed
with NSCLC by histological examination were tested for
EGFR mutations, and 50 patients that were positive for
EGFR mutations in the primary tumor samples were ran-
domly selected for further evaluation. Their clinical and
pathological characteristics are listed in Table 1. All study
subjects never received TKI treatment before the study,
and the formalin-fixed paraffin-embedded (FFPE) speci-
mens were available for both the primary and metastatic
tumors. Patients consented to tissue specimen collec-
tion prospectively, and the study was approved by the
ethics committee of Henan Cancer Hospital, the Affiliated
Cancer Hospital of Zhengzhou University.Clinical specimens
Pathological diagnosis was established as NSCLC by
assessing the HE stained sections of formalin-fixed
paraffin-embedded primary tumors. The tumor con-
tents was >50% for slides prepared from primary tu-
mors, and >20% for those from lymph node metastases.
For each subject, four DNA samples corresponding to
the two lateral regions and one center region of the pri-
mary tumor specimen, as well as one from lymph node
metastases were prepared. For each sample, DNA was
isolated from no less than 5 pieces of consecutive 5 μmTable 1 Clinical characteristics of 50 advanced NSCLC
cases and the detection of EGFR mutations in primary
tumors and metastases
No. cases Mutation rates of
primary tumor (%)
Mutation rates
of metastases (%)
Age
>60 38 100 100
≤60 12 100 75
Gender
Male 11 100 72.7
Female 39 100 100
Type
Adenocarcinoma
49 100 95.9
Squamous cell
carcinoma
1 100 0
Stage
IIIB 28 100 89.3
IV 22 100 100
Smoking status
Smoker 10 100 80
Non-smoker 40 100 97.5slides of Formalin-fixed paraffin-embedded (FFPE) spe-
cimens that had been stored at room temperature for
less than 5 years.
Isolation of genomic DNA
Genomic DNA from the FFPE samples was isolated by
using QIAamp DNA FFPE Tissue Kit (Qiagen) according
to the manufacturer’s instructions. The DNA concen-
tration was measured by UV spectrometer and adjusted
to 20 ~ 50 ng/μl. DNA samples were stored at −20°C
before use.
Quantitative measurement of EGFR mutation ratio
45 types of EGFR mutations corresponding to hotspots
in exons 18, 19, 20 and 21 were detected by using Hu-
man EGFR mutation quantitative PCR detection kit
(ACCB, Beijing, China) according to the manufacturer’s
instructions. Real-time PCR were performed on Stratagene
Mx3000P PCR machine with the following settings: 95°C
for 10 min, followed by 40 cycles of 95°C for 15 sec and
60°C for 1 min. The mutant and wild-type alleles were
amplified separately, and the levels of each mutation in
the sample were calculated by normalizing to standard
curves. The mutation ratio was defined as [mutation ra-
tio % = level of mutants/(level of mutants + level of wild
type allele) × 100%].
Statistical analysis
Statistical analysis was carried out using SPSS version
16.0 software (SPSS Inc., Chicago, IL, US). Fisher’s exact
test was used to analyze whether the different categories
had different positive rates. Kappa test was used to
analyze whether the two sampling regions had consistent
outcomes. Wilcoxon matched pairs test was used to
compare the mutation ratios from the two regions. Two-
sided p < 0.05 was considered statistically significant.
Results
EGFR mutations in primary tumors and metastases
Of the 50 cases of NSCLC that had EGFR mutations in
primary tumors, exon 19 mutations (in-frame deletions
only) were present in 28 cases (56%), and exon 21 (L858R
point mutations only) mutations were detected in 22 cases
(44%). Mutations in exon 19 and 21 were mutually exclu-
sive and no multiple mutations were found. Of the metas-
tases samples, 47 were positive for EGFR mutation (94%
concordance with the detection in primary tumors), and
exon 19 and exon 21 mutations were detected in 26 cases
(55%, 93% concordance) and 21 cases (45%, 95% concord-
ance), respectively. Notably, all cases presented the same
mutation type in the matching primary and metastatic tu-
mors. EGFR mutation detection and the clinical character-
istics were listed in Table 1. Among the 50 subjects, only 3
(6%) had different test results for EGFR mutations in
Table 2 Quantitative measurement of EGFR mutation ratios in 3 primary tumor sites and one metastases of the
same patient
ID Mutation ratio (%) in different primary tumor sites Mutation
ratio (%) of
metastases
1 2 3 Median Deviation (%)*
E001 85.9 91.1 80.1 85.9 12.8 <10
E002 39.1 25.9 44 39.1 49.8 41
E003 <10 <10 <10 <10 0.0 <10
E004 82.2 76.7 66.9 76.7 20.3 13.3
E005 43.9 40.5 45.4 43.9 11.3 41.2
E006 35.4 42.7 39.3 39.3 18.7 <10
E007 70.1 71.8 66.5 70.1 7.6 72.9
E008 79.8 85.1 88.9 85.1 10.8 28.1
E009 66.1 64.3 49.3 64.3 28.0 45.9
E010 54.2 83.6 77.6 77.6 40.9 15.9
E011 <10 <10 <10 <10 0.0 <10
E012 <10 <10 <10 <10 0.0 <10
E013 44.7 27.2 49.1 44.7 54.3 22.9
E014 55.5 64.3 66.6 64.3 17.9 31.2
E015 18.7 23.6 13.9 18.7 51.8 Negative
E016 37.6 45.2 38.2 38.2 18.8 <10
E017 23.8 28.9 23.9 23.9 20.0 30.4
E018 62.3 69.6 58.2 62.3 18.0 43.8
E019 <10 <10 <10 <10 0.0 <10
E020 <10 <10 <10 <10 0.0 <10
E021 48.6 47 40.2 47 18.6 25.3
E022 28.6 35.1 34.9 34.9 19.8 20.9
E023 38.9 31.7 30.9 31.7 23.6 35.9
E024 <10 <10 <10 <10 0.0 <10
E025 44.9 38.4 45.1 44.9 15.7 <10
E026 78.9 75.2 79.2 78.9 5.1 54.9
E027 <10 <10 <10 <10 0.0 Negative
E028 67.3 54.7 55.3 55.3 21.3 52.1
E029 56.3 45.4 47.5 47.5 21.9 <10
E030 24.8 29.1 32.7 29.1 27.4 15.9
E031 59.7 48.1 55.3 55.3 21.3 42.8
E032 31.8 34.9 41.1 34.9 25.9 25.8
E033 <10 <10 <10 <10 0.0 <10
E034 33.8 30.1 27.7 30.1 20.0 28.9
E035 42.2 38.1 45.1 42.2 16.7 40.2
E036 <10 <10 <10 <10 0.0 Negative
E037 54.7 48.4 47.1 48.4 15.2 <10
E038 18.3 28.7 22.2 22.2 45.1 14.9
E039 40.2 41.8 30.2 40.2 31.0 28.9
E040 38.4 45.2 43.2 43.2 16.1 <10
E041 58.3 51.9 48.3 51.9 18.9 45.5
E042 45.3 40.2 42.6 42.6 11.9 45.9
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Table 2 Quantitative measurement of EGFR mutation ratios in 3 primary tumor sites and one metastases of the
same patient (Continued)
E043 <10 <10 <10 <10 0.0 <10
E044 51.1 55.3 44.8 51.1 20.8 32.7
E045 65.7 62.9 71.2 65.7 12.5 49.8
E046 28.9 29.8 33.1 29.8 13.7 19.6
E047 43.8 45.9 49.7 45.9 12.7 43.1
E048 67.3 63.2 52.2 63.2 24.8 33.8
E049 39.1 43.9 30.8 39.1 34.5 27.8
E050 28.9 21.8 21.6 21.8 30.3 22.5
*Mutation deviation (%) of primary tumors was defined as (Emax-Emin)/Emd × 100%, where Emax, Emin, and Emd are the maximum, minimum and median value
of EGFR mutation ratios at different primary tumor sites. If all three mutation ratios in primary sites were below 10%, the deviation was calculated as 0%.
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was insignificant (P = 0.242) as analyzed by Fisher’s exact
test.
EGFR mutations at different sites of primary tumors of
the same patient
We performed quantitative measurement of EGFR mu-
tations at different sites of primary tumors (Table 2).
The median mutation deviation for different primary
sites (see footnote of Table 2 for the formula of calcula-
tion) was 18.3% (with a range of 0.0% ~ 54.3%), indicat-
ing that the results of the quantitative measurement of
EGFR mutations in different sites of primary tumor in
the same patient have a high level of concordance.
Quantitative measurement of EGFR mutations in primary
tumors and metastases of the same patient
Although the qualitative measurement of EGFR muta-
tions in primary sites and metastases showed a high level
of concordance (94%), the quantitative measurements
had significant difference (Tables 2 and 3). The Kappa
value of the two groups was 0.615 (P < 0.01), indicating that
different sampling sites only had moderate concordance.
Overall, the mutation ratios of metastases is significantly
lower than those of primary tumors (P < 0.01) as analyzed
by Wilcoxon matched pairs test.
Discussion
NSCLC patients carrying EGFR mutations often benefit
from TKI treatments with reduced sizes of primaryTable 3 EGFR mutation ratios in primary tumor and
metastases of the same patients
EGFR mutation ratio No. cases %
Primary Metastases
>10% >10% 32 64%
<10% <10% or negative 10 20%
>10% <10% or negative 8 16%
<10% >10% 0 0tumors and metastases visualized by medical imaging. For
a subset of patients, however, TKIs treatment only dimin-
ished the primary tumors but had no effect on metastases,
and occasionally the metastases even became enlarged or
more numerous over time. It raises the questions whether
the abundance of EGFR mutations are different in differ-
ent primary tumor sites, and whether the abundance and
type of mutations are the same for primary tumors and
metastases. Our study revealed the following characteris-
tics of EGFR mutations.
First of all, although the mutation ratio in different
primary tumor sites varied (the median value ranged
from <10% to 85.9%) (Table 2), the deviation of the mu-
tation ratio in different primary sites was limited (me-
dian was 18.3% with a range of 0.0% ~ 54.3%) (Table 2),
indicating that different sites of primary tumor in the
same patient have a high level of concordance. During
the routine pathological evaluation of FFPE specimens
of primary tumors, EGFR mutations were often tested
only in one randomly chosen sample. Our study showed
that when the area of cancerous cells were greater than
50%, a randomly chosen sample may reliably represent
the type and ratio of mutations of EGFR in primary
tumors.
Secondly, when the EGFR mutations were present in
primary tumors, they could be detected in metastases with
a high concordance regardless of the mutation ratios. The
concordance of EGFR mutations in primary tumor and
metastases is 94%, and that for mutation ratios is 84%.
Moreover, different types of mutations, such as those in
exon 19 and 21, were also identified with high concor-
dances (93% and 95%, respectively), suggesting that the
type of mutation did not affect the detection rates.
In addition, mutation detection is also affected by the
proportion of cancerous cells in a sample. Therefore,
for metastases with a lower number of cancerous cells,
highly sensitive methods such as real-time PCR are
highly recommended.
Moreover, in comparison to those in primary tumor
sites, the mutation ratios in metastases were reduced and
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negative detection). These results suggest that the use
of metastases specimens might generate false negative
diagnosis for EGFR mutations that could have been
present in primary tumors. The decreased EGFR muta-
tion ratios in metastases suggest that EGFR mutations
may not be essential for metastasis, which may underlie
the lack of response to TKIs in metastases despite an
positive outcome for the primary tumors. Notably, in
this study we had one case of squamous cell carcinoma
that harbors EGFR exon 19 mutation in the primary
tumor, but the mutation was undetectable in metasta-
ses. It is unclear if it is due to the nature of squamous
cell carcinoma.
In addition to the different pathological nature of pri-
mary tumor and metastases, the inconsistency in the
identification of EGFR mutation may also be due to the
sensitivity of the detection methods. For instance, Sanger
sequencing may give a negative calling for samples with
a mutation ratio of <10%, and therefore leads to low
concordance for EGFR mutations in different samples of
the same patients. Our study showed that by using
quantitative real-time PCR, the positive identification of
mutations in primary tumor and metastases had a 94%
concordance, and for the quantitative measurement of
mutation ratio the concordance was 84%. Hence, metasta-
ses specimens could be used for mutation assessment if
the specimen for primary tumors is lacking, but the detec-
tion methods must be of high sensitivity. Recently, the
abundance of mutations of predictive biomarkers, such as
EGFR and KRAS, has drawn more attention [16-18]. It
has been shown that the abundance of EGFR mutations
predicts benefit from EGFR-TKI treatment for NSCLC
[16]. Similarly, colorectal cancer patients with low abun-
dance of KRAS mutation have been reported to benefit
from EGFR antibody therapy [17]. Precise quantification
of EGFR mutation abundance may become a trend in
clinic to help with a better patient selection and better
treatment strategies. To enable precise quantification of
mutation ratio, real time PCR with a standard curve such
as the method applied in this report serves as one of the
optimal options.
In this study, only subjects with EGFR mutations in
primary tumors were included, but it did not address
the issues of positive mutation detection in metastases
but negative in primary sites. Future studies should
combine the prognosis data of the patients that received
TKIs therapy and analyze the correlation between the
quantitative measurement of EGFR mutations in primary
and metastatic tumors and their response to TKIs, espe-
cially those with inconsistent measurement of EGFR
mutation status in those sites. These studies could pro-
vide guidance for doctors to make informed decision in
NSCLC treatment.Conclusions
Randomly chosen sample may reliably represent the type
and ratio of EGFR mutations in primary tumors. EGFR
mutation ratios in primary and metastatic tumors are
different. If metastatic tumors are used for EGFR muta-
tion detection, the sensitivity of the detection assay must
be taken into consideration.
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